Scarica l'app Stockscreener
3.0712
0.16%
-0.0088
Precedente Chiudi:
$3.08
Aprire:
$3.09
Volume 24 ore:
96,059
Relative Volume:
0.59
Capitalizzazione di mercato:
$202.34M
Reddito:
-
Utile/perdita netta:
$-64.20M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$57,000
1 W Prestazione:
-3.76%
1M Prestazione:
-35.94%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.90
$3.1199
Intervallo di 1 settimana:
$2.90
$3.355
Portata 52W:
$2.90
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Nome
Climb Bio Inc
Settore
Industria
Telefono
1-866-857-2596
Indirizzo
20 WILLIAM STREET, WELLESLEY HILLS
Confronta CLYM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CLYM | 3.07 | 202.34M | 0 | -64.20M | 57,000 | 0.00 |
| VRTX | 450.36 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.27 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.36 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.36 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Climb Bio Inc Borsa (CLYM) Ultime notizie
Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb Or Sink? - Barchart
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30% - Simply Wall St
Are Wall Street Analysts Predicting KKR Stock Will Climb or Sink? - MSN
Deep Track Capital, LP Reduces Stake in Climb Bio Inc - GuruFocus.com
Are Business Services Stocks Lagging Climb Global Solutions, Inc. (CLMB) This Year? - Yahoo Finance
Sri Lankan Stocks Climb, Information Technology Leads The Way - Finimize
Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases - TipRanks
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
iBio Reports Fiscal First Quarter 2025 Financial Results - The Manila Times
Climb Bio Secures FDA Clearance for SLE Drug Trial, Reports $217.9M Cash Position | CLYM Stock News - StockTitan
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - GlobeNewswire
Climb Bio Appoints Biotech Veteran Douglas Williams as Board Chair, Strengthens Leadership | CLYM Stock News - StockTitan
Sales climb for EcoSynthetix Inc. in Q3 - Pulp & Paper Canada
Climb Bio to Present at Upcoming Investor Conferences - GlobeNewswire
Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap - MSN
Humic Acid Market Set to Climb to USD 1.63 Billion by 2030 - openPR
ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb - MSN
Tevogen Bio (TVGN) Sees Major Stock Surge After Key AI Move - Stocks Telegraph
Interpublic Group Of Cos., Inc. (IPG): Worth A Small Bite At $32.03 - Stocks Register
Why Lamb Weston Stock Was Climbing Today - Yahoo Finance
Big Bank Stocks Climb. 3 Stocks to Consider Adding to Your Portfolio. - Yahoo Finance
Merck & Co’s Clesrovimab Has Beyfortus Hill To Climb In RSV - Citeline News & Insights
Treasury Yields Climb as Strong Data Sow Doubt on Fed Rate Cuts - Yahoo Finance
Mortgage Demand Sees Sharpest Weekly Drop Since April 2020 As Rates Climb Above 6.5% - Yahoo Finance
Korean growth stocks climb after rate cut - 코리아타임스
Vale Achieves Six-Year High in Iron Ore Output, Copper and Nickel Production Also Climb - Yahoo Finance
European Wax Center Continues to Climb in Franchise Times' Top 400 Ranking - Yahoo Finance
US Mortgage Rates Climb to 6.52%, Highest Since Early August - Yahoo Finance
What You Need to Know Ahead of Bio-Techne's Earnings Release - TradingView
Stocks of B. Riley Financial Inc (RILY) are poised to climb above their peers - SETE News
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event - The Manila Times
‘Retirement super pot’ holders pay themselves around £3m each in a year - Yahoo Finance UK
Climb Bio to present kidney disease treatment study By Investing.com - Investing.com Australia
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewswire
Climb Bio to present kidney disease treatment study - Investing.com India
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology - The Bakersfield Californian
A stock that deserves closer examination: Climb Bio Inc. (CLYM) - US Post News
Climb Global (CLMB) Surged on Strong Results - Yahoo Finance
Quarterly IPOs Climb Back Above $1bn - Scrip
US 30-Year Mortgage Rate Climbs by Most in More Than a Year - Yahoo Finance
Climb Global (CLMB) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - ForexTV.com
Climb Bio to Present at William Blair’s Upcoming Conference - GlobeNewswire
Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - The Manila Times
Intumescent Coatings Market Size to Climb to USD 2.4 - GlobeNewswire
Intumescent Coatings Market Size to Climb to USD 2.4 billion by 2034 with a 7.4% CAGR, Supported by Steel Fabrication Fireproofing Demand | States Transparency Market Research, Inc. - Yahoo Finance
Climb Bio Inc Azioni (CLYM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Climb Bio Inc Azioni (CLYM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morisset Valerie | EVP, R&D AND CSO |
Jul 22 '24 |
Sale |
8.03 |
69,005 |
554,170 |
31,317 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 19 '24 |
Sale |
7.21 |
60,201 |
434,325 |
100,322 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 18 '24 |
Sale |
6.93 |
38,576 |
267,332 |
160,523 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 17 '24 |
Sale |
6.91 |
3,207 |
22,160 |
199,099 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 16 '24 |
Sale |
7.13 |
50,000 |
356,500 |
202,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 12 '24 |
Sale |
7.07 |
50,000 |
353,500 |
294,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 15 '24 |
Sale |
7.01 |
42,377 |
297,063 |
252,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 11 '24 |
Sale |
7.11 |
50,000 |
355,500 |
344,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 10 '24 |
Sale |
6.83 |
50,000 |
341,500 |
394,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 09 '24 |
Sale |
6.66 |
5,931 |
39,500 |
444,683 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):